On September 8, 2016, the Board instituted an IPR of U.S. Patent No. 6,331,415, one of the Cabilly patents owned by Genentech. The Petitioner in IPR2016-00710 is Mylan.  The ’415 patent was the subject of two other IPRS that were terminated last week following settlements between Genentech and those Petitioners, Sanofi-Aventis and Genzyme, as we reported.  The institution decision in the ’710 IPR and all other important IPR documents on biologic patents are posted on our IPR tracker page.